Clinical trials: Glucosamine
Breast Cancer, Joint Pain
Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer
Investigators are hoping to learn if glucosamine with chondroitin can help relieve joint pain/stiffness associated with aromatase inhibitors.
- Trial name
- NCT00691678
- Testing
- Chondroitin, Glucosamine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Dawn L. Hershman
Inflammation, Knee Pain Chronic
Effects of UC-II, Glucosamine and Curcumin Supplementation on Knee Pain and Inflammation.
This research evaluated the effects of UCII, glucosamine and curcumin supplementation on knee pain and inflammation.
- Trial name
- NCT06581094
- Testing
- UCII, glucosamine and curcumin
- Where
- Taiwan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University
Low Back Pain
The Glucosamine-study: The Effect of Glucosamine in Treatment of Chronic Low Back Pain
Low back pain (LBP) is the most frequent cause of sick leave and disability pension, and degenerative and osteoarthritic (OA) changes is a significant cause of pain and disability.
- Trial name
- NCT00404079
- Testing
- Glucosamine sulphate
- Where
- Norway
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Ullevaal University Hospital
Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles
Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)
The objective of this study is to evaluate the long-term safety and efficacy of Ace-ER treatment in subjects with GNEM.
- Conditions
- Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles, Distal Myopathy, Nonaka Type, GNE Myopathy
- Trial name
- NCT02736188
- Testing
- Aceneuramic Acid Extended-Release Tablets
- Where
- 14 sites in United States, Bulgaria and 5 more
- Volunteers
- 143 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteoarthritis of the Knee
Efficacy and Safety Study of Glucosamine/Chondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee
The purpose of this study is to assess the efficacy and safety of glucosamine and chondroitin sulfate association in the treatment of patients with osteoarthrosis of the knee.
- Trial name
- Artico (NCT00955552)
- Testing
- Glucosamine sulphate and chondroitin sulphate association, Cosamin DS® (Nutramax)
- Where
- 4 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Eurofarma Laboratorios S.A.
Coronavirus, Covid19
N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
This study examines the efficacy of N-acetylglucosamine (NAG) in treating patients with novel coronavirus (COVID-19) infection.
- Trial name
- NCT04706416
- Testing
- N-acetyl glucosamine (NAG), Control
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Quantinosis.ai LLC
Knee Osteoarthritis
Efficacy and Safety of a New Formulation of Chondroitin Sulfate and Glucosamine Sulfate to Treat Knee Osteoarthritis
The main objective is to assess the efficacy of a new formulation containing chondroitin sulfate and glucosamine sulfate (CS+GS) compared with placebo in patients with primary osteoarthritis of the knee.
- Trial name
- NCT01893905
- Testing
- CS+SG
- Where
- Spain
- Volunteers
- 158 people
- Sponsor
- Tedec-Meiji Farma, S.A.
Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles
A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment
The primary objective of this Phase 2 study is to evaluate the safety of open-label 6 g/day Ace-ER in GNEM participants with severe ambulatory impairment.
- Conditions
- Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles, Distal Myopathy, Nonaka Type, GNE Myopathy
- Trial name
- NCT02731690
- Testing
- Aceneuramic Acid Extended-Release
- Where
- 5 sites in United States, Bulgaria and 1 more
- Volunteers
- 42 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
GNE Myopathy, Hereditary Inclusion Body Myopathy (HIBM)
An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy
The safety objectives of the study are to: evaluate additional long-term safety of SA-ER treatment of participants with GNE myopathy previously treated with SA-ER at dose of 6g/day (Part I); evaluate the safety of 12g /day SA…
- Trial name
- NCT01830972
- Testing
- SA-ER 500 mg, SA-IR 500 mg
- Where
- 4 sites in United States, Israel
- Volunteers
- 59 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Knee Osteoarthritis
Study on Efficacy and Safety of Chondroitin Sulfate + Glucosamine Hydrochloride Versus Celecoxib in Knee Osteoarthritis
The purpose of this study is to determine whether the combination of Chondroitin sulfate (CS) and Glucosamine Hydrochloride (GH) has similar efficacy to Celecoxib (CE) in the treatment of patients with moderate to severe knee…
- Trial name
- MOVES (NCT01425853)
- Testing
- Chondroitin/Glucosamine (Droglican), Celecoxib
- Where
- Spain
- Volunteers
- 606 people
- Sponsor
- Bioiberica
Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles
Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)
The primary objective of this study is to evaluate the effect of 6 g/day aceneuramic acid extended-release (Ace-ER) treatment of participants with GNEM on upper extremity muscle strength (upper extremity composite [UEC] score) as…
- Conditions
- Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles, Distal Myopathy, Nonaka Type, GNE Myopathy
- Trial name
- GNEM (NCT02377921)
- Testing
- aceneuramic acid extended-release (Ace-ER)
- Where
- 13 sites in United States, Bulgaria and 5 more
- Volunteers
- 89 people
- Sponsor
- Ultragenyx Pharmaceutical Inc